Skip to content
Screener

Aurinia Pharmaceuticals AUPH Financing Cash Flow

Financing Cash Flow at other companies

Rogers Corporation logo
Rogers CorporationROG
-$3M+89.3%
Vera Therapeutics logo
Vera TherapeuticsVERA
$3.94M+157%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$4.65M-166%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$5.58M-553%
Opko Health logo
Opko HealthOPK
-$13.03M+83.6%

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+35.7%
Enterprise value$1.98B+25.5%
P/E6.6×-18.6×
P/S6.7×+0.8×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:23 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001600620-26-000049
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payments of principal portion of Monoplant finance lease liability(3,653)(2,771)
Proceeds from issuance of common shares for equity awards7139,288
Tax withholding payments related to net settlements of equity awards(14,580)(8,933)
Cash flows from financing activities(53,685)(49,337)
Net decrease in cash, cash equivalents and restricted cash(39,205)(17,005)
Cash, cash equivalents and restricted cash, beginning of the period80,21383,433
Cash, cash equivalents and restricted cash, end of the period$41,008$66,428
Supplemental cash flow information:

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's financing cash flow?
Aurinia Pharmaceuticals (AUPH) reported financing cash flow of -$53.69M in Q1 2026.
How has Aurinia Pharmaceuticals's financing cash flow changed year-over-year?
Aurinia Pharmaceuticals's financing cash flow decreased by 8.8% year-over-year, from -$49.34M to -$53.69M.
What is the long-term trend for Aurinia Pharmaceuticals's financing cash flow?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's financing cash flow has grown at a -16.8% compound annual growth rate (CAGR), from $221.11M to -$106.11M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Aurinia Pharmaceuticals's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude